Originally published on August 24, 2016 on the Enigma blog.
For a critical lens on how drug pricing is set, click here. All views are my own.
Mylan CEO Heather Bresch has been vilified by the press these past few weeks for the 400%…
On the morning of August 5, 2016, pharmaceutical giant Bristol Myers-Squibb (BMS) announced that its drug, Opdivo (nivolumab), failed a major lung cancer clinical trial. Almost instantaneously, BMS lost…
“The really important thing about data is the more things you have to connect together, the…
I’ll be splitting this series over several articles, with each focusing on a different set of the candidates’ drug pricing proposals. To read part 1 of this series on the role of pharmaceutical companies in drug pricing, click here…
I’ve gotten a lot of great questions on drug pricing, and I’d like to pause here to answer a few before moving onto my next post on presidential candidates’ proposals to fight rising drug costs. These questions…
This is part 2 of a 3-part blog post on drug pricing. To read part 1 of this series on the role of pharma companies, click here. Part 3 will focus on the policies our 2016 presidential candidates are proposing.
This is a short supplemental piece on how Medicaid/Medicare set drug prices.(Click here to view the main article on the role of payers.)
As much as healthcare is a fundamental right, capitalism still reigns as one of the…
This will be a 3-part blog post on a) how pharmaceutical companies set prices for drugs in the U.S. b) the role insurance companies and Medicare/Medicaid play in this system and c) how effective the…
